Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

If you have heart valve replacement surgery, you will be prescribed a blood thinner (a.k.a. an anticoagulant) upon discharge from the hospital. Long-term blood thinner medication guidelines differ ...

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic, APAC, to primarily support the initiation of a Phase IIa trial for ...

Aplagon announces EUR 7 million financing to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2A trials: Helsinki Tuesday, February 4, 2025, 16:00 Hrs [IS ...

Left atrial appendage closure (LAAC) in patients at moderate to high risk for stroke who were undergoing catheter atrial fibrillation (AFib) ablation resulted in significantly less bleeding compared ...

Study performed at the Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain.

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...

There are anticoagulants such as warfarin, heparin, and new oral medications like rivaroxaban and apixaban. These have been widely applied in patients with atrial fibrillation, a clinical ...

For decades, unfractionated heparin (hereafter, heparin) has been the primary anticoagulant used for extracorporeal membrane oxygenation (ECMO) support. More recently, however, bivalirudin, a direct ...

Although low-molecular-weight heparin (LMWH) has been recommended to prevent venous thromboembolism, its anticoagulant and anti-inflammatory effects in sepsis remain controversial. Owing to the ...

PORTLAND, OR, UNITED STATES, January 31, 2025 /EINPresswire / -- The global heparin market is experiencing substantial growth as demand for effective anticoagulant therapies increases worldwide.

An­thos Ther­a­peu­tics’ an­ti­co­ag­u­lant pos­es a low­er risk of bleed­ing events than Bay­er and J&J’s Xarel­to when used to pre­vent blood clots in atri­al fib­ril­la ...